On December 18, BeiGene announced that the US Food and Drug Administration has granted its self-developed pipeline drug GPC3x4-1bb bispecific antibody BGB-B2033 fast-track certification to treat adult patients with hepatocellular carcinoma whose disease progresses during or after previous systemic treatment.

Zhitongcaijing · 2d ago
On December 18, BeiGene announced that the US Food and Drug Administration has granted its self-developed pipeline drug GPC3x4-1bb bispecific antibody BGB-B2033 fast-track certification to treat adult patients with hepatocellular carcinoma whose disease progresses during or after previous systemic treatment.